bereznet.ru


Clovis Oncology Stock

Clovis Oncology Inc (CLVS) ; Market Capitalization, $K · 11,, 11, ; Shares Outstanding, K · ,, 11, ; Annual Sales, ,,, 0 ; Annual Net Income. By Colin Kellaher Shares of Clovis Oncology Inc. slid nearly 10% in premarket trading Monday after the biopharmaceutical company said it filed for chapter View Clovis Oncology (CLVS) stock price, news, historical charts, analyst ratings, financial information and quotes on Futubull. Trade commission-free with. Discover all the factors affecting Clovis Oncology's share price. CLVSQ is currently rated as a null | Stockopedia. View Clovis Oncology (CLVS) stock price, news, historical charts, analyst ratings, financial information and quotes on Moomoo. Trade commission-free with.

Clovis Oncology Inc (CLVSQ) ; P/E Ratio, 0 ; Dividend Yield, 0 ; EPS, ; Price to Revenue, 0 ; Debt to Equity, Clovis Oncology (NASDAQ:CLVS) released its quarterly earnings data on Wednesday, November, 3rd. The biopharmaceutical company reported ($) earnings per. Looking to buy Clovis Oncology Stock? View today's CLVS stock price, trade commission-free, and discuss CLVS stock updates with the investor community. CLOVIS ONCOLOGY INC. interactive chart · 02/03/ - · · 0 · 1. Clovis Oncology Market Momentum ; Rate Of Daily Change, ; Day Median Price, ; Day Typical Price, ; Market Facilitation Index, ; Price Action. A high-level overview of Clovis Oncology, Inc. (CLVSQ) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and. Clovis Oncology, Inc. (CLVS): $ · Get Rating · Component Grades · Latest CLVS News From Around the Web · Continue Researching CLVS. All information about Clovis Oncology - stock price, quote chart, key statistics, dividends, company news and more. Stock price for similar companies or competitors ; Clovis Oncology Logo · BioMarin Pharmaceutical. BMRN. $, % ; Clovis Oncology Logo · AstraZeneca. AZN. Clovis Oncology Inc(LTS:0A7C) does not pay dividend. Press Release. Subject, Date. No Press Release.

The Clovis Oncology, Inc. stock price is closed at $ ( shares outstanding). The Clovis Oncology, Inc. is trading on NASDAQ with the sign CLVS. Clovis. CLVSQ Clovis Oncology Inc. 28, $ $ (%). Today. Watchers, 28, Wk Low, $ Wk High, $ Market Cap, $M. Is Clovis Oncology stock a Buy, Sell or Hold? Clovis Oncology stock hasn't recieved a clear consensus rating. The average rating score is and is based on 0 buy. Clovis Oncology (CLVSQ) has a Smart Score of N/A based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge Fund. CLVSQ Clovis Oncology, Inc. Stock Price & Overview​​ CLVSQ is defunct since July 21, CLVS - CLVS STOCK NEWS · Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP · Clovis Oncology Presents Data from TRITON3. Company profile page for Clovis Oncology Inc including stock price, company news, executives, board members, and contact information. Clovis Oncology Inc (US:CLVS) has 2 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents.

bereznet.ru provides you with Clovis Oncology Inc share price (CLVS) listed in the stock exchange, including the low, high, opening and closing price. PRO. Clovis Oncology Charts Suggest Aggressive Buying. The technical signs indicate the stock's price and volume are going up without a dip. Get Clovis Oncology Inc historical price data for CLVSQ stock. bereznet.ru has all the historical stock data including the closing price, open, high, low. CLVS / Clovis Oncology Inc short borrow fee rates are shown in the following table. This table shows the interest rate that must be paid by a short seller of US. Get Clovis Oncology Inc historical price data for CLVSQ stock. bereznet.ru has all the historical stock data including the closing price, open, high, low.

Glencore Stock Forecast | Create A Virtual Stock Portfolio


Copyright 2017-2024 Privice Policy Contacts SiteMap RSS